Delivery Order 36F79718D0509-36C26322F0071

This is a firm-fixed-price delivery order contract awarded by the Veterans Integrated Service Network 5 (VISN 5), a civilian agency within the U.S. Department of Veterans Affairs. The contract is for the pharmaceutical product Belzutifan (Welireg) 40 mg, a cancer treatment drug manufactured by Merck Sharp & Dohme LLC, doing business as Merck. The contract has a ceiling value of $22,051.39 and an ultimate completion date of June 6, 2025. Merck is the prime contractor, and there is no...

This federal contract was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Neurocrine Biosciences, Inc., a biopharmaceutical company, to provide VALBENAZINE capsules. VALBENAZINE is used to treat neurological movement disorders and is being delivered to VA locations, primarily within Veterans Integrated Service Network 12 in California. The contract is a firm fixed price delivery order issued against Neurocrine's listing on the General Services...

This is a delivery order awarded by the Veterans Integrated Service Network 20 (VISN 20), part of the U.S. Department of Veterans Affairs (VA), to Merck Sharp & Dohme LLC (Merck), a major pharmaceutical manufacturer. The contract is for the supply of Welireg (belzutifan), a cancer treatment drug, with a ceiling value of $259,543.18 and a period of performance ending on September 30, 2025. The contract is not set aside and is issued under Merck's Federal Supply Schedule (FSS) contract for...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 awarded a $677,821.50 firm fixed price delivery order against Neurocrine Biosciences, Inc.'s Pharmaceuticals and Drugs GSA Schedule contract. This order is to provide VALBENAZINE 40MG and 80MG capsules for the Hines CMOP, indicating the capsules will support treatment programs at the Captain James A. Lovell Federal Health Care Center in Illinois. Neurocrine Biosciences will serve as the prime...

This federal contract award is for SOTATERCEPT - EMERGENCY, a delivery order with a ceiling value of $10,627.51, awarded to Merck Sharp & Dohme LLC (doing business as Merck), a major pharmaceutical manufacturer. The contract is a Firm Fixed Price type, under Merck's Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs. The award was made by the Veterans Integrated Service Network 9 (VISN 9), a civilian agency within the Department of Veterans Affairs. The contract...

Recordati Rare Diseases, Inc. was awarded a delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5. The $21,756.52 firm fixed price order is for the delivery of pasireotide 40 mg to Bartlett, Tennessee, with completion by January 20, 2023. No set-aside designation was applied to this order placed under GSA Schedule contract FSS-61-IB, which provides pharmaceutical...

Actelion Pharmaceuticals US, Inc. was awarded a $14,548.29 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21. The firm fixed price order is for the drug UPTRAVI 1200MCG and has a completion date of April 20, 2023. Performance will take place in North Las Vegas, Nevada. No set-aside designation was used for this order to supply pharmaceutical...

This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Daiichi Sankyo, Inc., a for-profit pharmaceutical manufacturer, for the provision of the drug pexidartinib (marketed as TURALIO) in 125mg capsule form. The $73,651.68 delivery order was placed against Daiichi Sankyo's existing Blanket Purchase Agreement (BPA) with the VA National Acquisition Center under the GSA Pharmaceuticals and Drugs Schedule. This unrestricted...

This federal contract award to Otsuka America Pharmaceutical Inc. is a Delivery Order with a ceiling value of $362,719.21. The contract is issued under a Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs (VA) for Pharmaceuticals and Drugs (FSS-61-IB). The award is for the drug Jynarque (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease and hyponatremia. Otsuka America Pharmaceutical is a for-profit pharmaceutical manufacturer that...

This federal contract award was issued by the Department of Veterans Affairs (VA) to Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer and supplier. The contract, valued at $12,559.90, is for the delivery of the drug JYNARQUE (tolvaptan) in 90mg-30mg dosages. JYNARQUE is used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract is a Delivery Order under Otsuka's existing Federal Supply Schedule (FSS) contract with the VA, which has a...